<DOC>
	<DOCNO>NCT00305526</DOCNO>
	<brief_summary>This protocol evaluate effect cardiac resynchronization therapy ( CRT ) combine beta-blocker therapy patient symptomatic heart failure beta-blocker therapy either tolerate could titrate optimal dos CRT . Cardiac resynchronization therapy combine automatic implantable cardioverter defibrillator ( AICD , CRT-D ) show associated improvement prognosis patient leave ventricular systolic dysfunction heart failure .</brief_summary>
	<brief_title>REBEAT Resynchronisation Beta-Blocker European Trial</brief_title>
	<detailed_description>The purpose investigation evaluate effect CRT combine beta-blocker therapy patient symptomatic heart failure beta-blocker therapy either tolerate could up-titrated optimal dos CRT .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<criteria>Symptomatic heart failure indication cardiac resynchronization therapy ( CRT ) , Hemodynamic stability document intolerance betablocker therapy treatment betablocking agent suboptimal dosage ( &lt; 25 % optimal dosage ) . chronic atrial fibrillation ; indication permanent antibradycardia pacing ; mechanical tricuspid valve ; Severe aortic stenosis primary valve disease cause cardiomyopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>